As previously reported in meta-analyses, the rate of hypoglycemia was not higher in T2DM patients treated with the DPP-4 inhibitors, even in patients already undergoing treatment with insulin or a sulfonylurea [31, 32]. The gene discussed is INS; the disease is type 2 diabetes mellitus.